Irbesartan treatment does not influence plasma levels of the advanced glycation end products CML and CEL in patients with type 2 diabetes and microalbuminuria. An IRMA2 substudy

Engelen, L., Persson, F., Ferreira, I., Rossing, P., Hovind, P., Teerlink, T., Stehouwer, C. D. A., Parving, H. -H. and Schalkwijk, C. G. (2010). Irbesartan treatment does not influence plasma levels of the advanced glycation end products CML and CEL in patients with type 2 diabetes and microalbuminuria. An IRMA2 substudy. In: 46th Annual Meeting of the European Association for the Study of Diabetes (EASD), Stockholm, Sweden, (). 20-24 September 2010.

Author Engelen, L.
Persson, F.
Ferreira, I.
Rossing, P.
Hovind, P.
Teerlink, T.
Stehouwer, C. D. A.
Parving, H. -H.
Schalkwijk, C. G.
Title of paper Irbesartan treatment does not influence plasma levels of the advanced glycation end products CML and CEL in patients with type 2 diabetes and microalbuminuria. An IRMA2 substudy
Conference name 46th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Conference location Stockholm, Sweden
Conference dates 20-24 September 2010
Journal name Diabetologia   Check publisher's open access policy
Place of Publication Heidelberg, Germany
Publisher Springer
Publication Year 2010
Year available 2010
Sub-type Published abstract
Open Access Status
ISSN 0012-186X
1432-0428
Volume 53
Issue 1 Suppl.1
Total pages 2
Language eng
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Conference Paper
Collection: School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Tue, 19 May 2015, 18:49:45 EST by System User on behalf of School of Public Health